Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.58 per share a year ago.
Why the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained Today
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $52.06, representing a +2.1% change from its previous close.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?
CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $56.42, indicating a +1.58% shift from the previous trading day.
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
CRISPR Therapeutics plans to post clinical trial updates for multiple candidates this year. The company's stock could jump if it can impress the market.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $55.72, marking a -1.83% move from the previous day.
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today
What if the biggest winners in biotech weren't the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible?
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.51, moving +1.43% from the previous trading session.
